Eli Lilly is much more than just a weight loss stock.

After nearly tripling between 2023 and the end of 2025, Lilly is undergoing a steep sell-off in 2026.

If you are interested in buying Eli Lilly (NYSE: LLY) today, it is most likely because of the success of the company's GLP-1 ...

It's not much of a contest right now.

Eli Lilly has asked the U.S. Supreme Court to overturn a part of a Civil War-era law that allows private whistleblowers to ...

Janus Henderson Investors, an investment management company, released its “Forty Fund” fourth-quarter 2025 investor letter. A ...

Eli Lilly, the maker of Zepbound and Mounjaro, said its experimental GLP-1 pill successfully helped adults with obesity lose weight in a Phase 3 trial, as the company moves closer to submitting the ...

It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting impressive results following a large, robust 72-week trial that saw obese ...

Eli Lilly and the "societal obligation" of GLP-1s, Merck's Terns Pharma purchase, and more biotech news in today's Readout ...

You might be surprised to hear this, but off-the-shelf CAR-T therapies for cancer are still a thing. We preview an ...